AstraZeneca PLC filings document the disclosures of a foreign private issuer focused on prescription medicines across oncology, rare diseases, cardiovascular, renal and metabolism, respiratory, and immunology. The company’s Form 6-K reports include quarterly operating results, product sales, alliance and collaboration revenue, EPS measures, and management commentary on medicine performance and pipeline progress.
Other filings record FDA advisory-committee and approval updates for medicines such as TRUQAP, BREZTRI, SAPHNELO, camizestrant, and ULTOMIRIS; Phase III trial disclosures; licensing arrangements; Board changes; total voting rights; and admission of additional ordinary shares. These documents also provide capital-structure and governance information relevant to AstraZeneca’s UK issuer framework and SEC foreign-issuer reporting obligations.
AstraZeneca reported that its IL-33-targeting biologic tozorakimab met the primary endpoint in the Phase III MIRANDA trial in chronic obstructive pulmonary disease (COPD). The drug produced a statistically significant and clinically meaningful reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and in the overall trial population.
This is the third positive pivotal Phase III trial for tozorakimab in COPD, following the OBERON and TITANIA studies, reinforcing evidence of benefit on top of standard inhaled therapies. Tozorakimab 300mg every two or four weeks was generally well tolerated with a favourable safety profile consistent with earlier trials, and the data will be submitted to regulatory authorities and shared at an upcoming medical meeting.
AstraZeneca PLC reported that all resolutions at its Annual General Meeting held on 9 April 2026 were approved by poll vote. Shareholders received the 2025 accounts, confirmed the 2025 interim dividends, and appointed KPMG LLP as auditor, authorising the directors to set the auditor’s remuneration.
All directors standing for re-election, including Pascal Soriot and Aradhana Sarin, were re-elected, with support generally above 97%, except Marcus Wallenberg who received 83.80% of votes cast. Shareholders approved the remuneration report and renewed the French appendix to the performance share plan.
Authorities were granted to allot shares and to disapply and further disapply pre-emption rights, and to permit the company to purchase its own shares, with 99.81% of votes cast in favour of the share repurchase authority. As at 7 April 2026, issued share capital comprised 1,550,988,781 ordinary shares eligible to vote at the AGM.
AstraZeneca PLC notified the New York Stock Exchange of the voluntary withdrawal of its 0.700% Notes due 2026 from listing and registration on the NYSE. The Exchange certified compliance with Rule 12d2-2 and the issuer complied with the Exchange rules governing voluntary withdrawal.
AstraZeneca reported positive Phase III results from the EMERALD-3 trial in earlier-stage, unresectable hepatocellular carcinoma eligible for embolisation. The regimen combining Imfinzi (durvalumab), Imjudo (tremelimumab), lenvatinib and transarterial chemoembolisation (TACE) achieved a statistically significant and clinically meaningful improvement in progression-free survival versus TACE alone.
At an interim analysis, the combination also showed a trend toward improved overall survival, and a STRIDE regimen plus TACE arm showed strong trends for both progression-free and overall survival, although not yet formally tested. Safety was consistent with known profiles, and the trial will continue to follow overall survival and other secondary endpoints while data are shared with global regulators.
AstraZeneca PLC reported updated share capital and voting rights information. As at 31 March 2026, the company had 1,550,980,823 ordinary shares of US$0.25 in issue, all with voting rights and none held in treasury, so total voting rights equal this amount.
The company also confirmed the admission to trading on the London Stock Exchange of 491 additional ordinary shares issued under its employee share schemes between 20 and 31 March 2026, under an existing block admission dated 29 January 2021. These new shares are fully fungible with existing ordinary shares.
AstraZeneca, through its Alexion rare disease unit, reported positive global Phase III results for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy for hypophosphatasia (HPP).
In children who had never received Strensiq, the MULBERRY trial met its primary endpoint, showing statistically significant and clinically meaningful bone health improvements on the Radiographic Global Impression of Change score at week 25, with supportive gains in rickets severity and physical function measures. The CHESTNUT switch study in paediatric patients previously treated with Strensiq showed efzimfotase alfa was well-tolerated and maintained bone benefits while offering less frequent dosing.
In adolescents and adults, the HICKORY trial did not achieve statistical significance on the primary Six-Minute Walk Test endpoint versus placebo, largely due to better-than-expected placebo performance in adult-onset HPP, but showed nominally significant benefits in fatigue and in prespecified subgroups with paediatric-onset HPP across mobility, function and pain. Across all three studies, efzimfotase alfa demonstrated an acceptable safety profile, and AstraZeneca plans to present the data at a medical meeting and share them with global regulators.
AstraZeneca reported that its investigational biologic tozorakimab met the primary endpoint in both Phase III OBERON and TITANIA trials in patients with COPD. The drug significantly reduced the annualised rate of moderate-to-severe COPD exacerbations versus placebo in former smokers and in the overall population, on top of inhaled standard of care.
Tozorakimab is a potential first-in-class monoclonal antibody targeting IL‑33, uniquely blocking both reduced and oxidised forms to address inflammation and mucus dysfunction. It was generally well tolerated with a favourable safety profile. Additional Phase III COPD trials, PROSPERO and MIRANDA, are ongoing with results expected in H1 2026.
AstraZeneca PLC has admitted 45,750 new ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market. These shares were issued between 20 January 2026 and 19 March 2026 under the company’s existing block admission.
The new shares arise from AstraZeneca’s employee share schemes, meaning they were created to satisfy staff share awards or options. Following this admission, the total number of AstraZeneca ordinary shares in issue is 1,550,980,332, all fully fungible with the existing stock.
ASTRAZENECA PLC officer Mani Sharma filed an initial insider ownership report, listing current equity and award holdings in the company. Sharma directly holds 31,153.4659 ordinary shares, plus equity awards that may convert into additional shares over time.
The filing shows 2,996.3080 restricted stock units, each representing a right to receive one ordinary share that vests on November 16, 2028, with shares to be delivered on November 17, 2028. There are also 31.2970 dividend equivalent rights, which accrue on these RSUs and convert into ordinary shares on the same vesting date.
In addition, Sharma holds an employee stock option covering 195 ordinary shares at an exercise price of $123.9800 per share, exercisable from December 1, 2028 until June 1, 2029. The exercise price is originally denominated at GBP93.64, with the reported dollar value based on a stated exchange rate.
AstraZeneca PLC reports that its immunotherapy Imfinzi (durvalumab), combined with standard FLOT chemotherapy, has been approved in the EU as the first perioperative immunotherapy for adults with resectable Stage II-IVA gastric and gastroesophageal junction cancers. The regimen is given before and after surgery, then continued as Imfinzi alone.
The approval is based on the Phase III MATTERHORN trial, where Imfinzi plus FLOT cut the risk of disease progression, recurrence or death by 29% (event-free survival HR 0.71; p<0.001) versus chemotherapy alone, with higher one- and two-year event-free rates. Final overall survival data showed a 22% reduction in the risk of death (HR 0.78; p=0.021), with an estimated 69% of patients alive at three years compared with 62% on chemotherapy alone. The safety profile and surgery completion rates were similar between arms.